2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World
19 nov. 2024 08h00 HE
|
BioTech Breakthrough
LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
[Latest] Global Life Reinsurance Market Size/Share Worth USD 735.6 Billion by 2033 at a 12.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
01 juil. 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, July 01, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Life Reinsurance Market Size, Trends and Insights By Type (Facultative...
Hampton Creek Press (print and distribution provided by Simon & Schuster) Announces Behind a Closed Door, the Latest Novel by Writer J.D. Barker
17 avr. 2024 13h51 HE
|
Hampton Creek Press
The long-awaited thriller from New York Times bestselling author J.D. Barker is available for preorder now and will be released on May 13, 2024.
aTyr Pharma to Participate in April Investor Conferences
01 avr. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
29 janv. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
13 nov. 2023 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
09 nov. 2023 16h00 HE
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
11 sept. 2023 08h00 HE
|
aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
“The Life Cycle” Podcast from Klang Games Clarifies the Most Important Questions About the Future of Mankind
06 avr. 2023 09h30 HE
|
Klang Games
BERLIN, April 06, 2023 (GLOBE NEWSWIRE) -- Klang Games, the makers behind the sandbox simulation MMO game SEED, are not only concerned with the future of mankind and the colonization of exoplanets...
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
20 mars 2023 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its...